Wilms tumor 1 peptide-HLA class I complex (WT1-HLA-I complex)

The Wilms tumor 1 (WT1) peptide-HLA class I complex is a molecular assembly presented on the surface of cells, consisting of a processed peptide fragment derived from the WT1 protein bound within the groove of a Human Leukocyte Antigen (HLA) class I molecule. WT1 is a zinc-finger transcription factor that plays a critical role in cell growth and differentiation; while it is essential during embryonic urogenital development, its expression in healthy adults is highly restricted to specific tissues like renal podocytes and hematopoietic stem cells. However, WT1 is significantly overexpressed in a wide range of hematological malignancies and solid tumors, where it functions as an oncogene, making the WT1-HLA complex a premier target for cancer immunotherapy. The complex is specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, which can trigger the selective destruction of tumor cells. Current therapeutic approaches targeting this complex include peptide-based vaccines designed to expand endogenous WT1-specific T cells, TCR-engineered T-cell (TCR-T) therapies, and TCR-mimic antibodies or bispecific T-cell engagers that recognize the peptide-HLA interface with antibody-like affinity.

Other names

WT1-MHC class I complexWT1/HLA-A*02:01 complexWT1-pMHCWilms tumor protein 1 peptide-MHC complex

T-cell receptor (TCR) binding, T-cell mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC) via TCR-mimic antibodies